KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Equity Average: 2019-2025

Historic Equity Average for Castle Biosciences (CSTL) over the last 6 years, with Sep 2025 value amounting to $461.2 million.

  • Castle Biosciences' Equity Average rose 6.64% to $461.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $461.2 million, marking a year-over-year increase of 6.64%. This contributed to the annual value of $423.6 million for FY2024, which is 7.17% up from last year.
  • As of Q3 2025, Castle Biosciences' Equity Average stood at $461.2 million, which was up 2.99% from $447.8 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Equity Average ranged from a high of $461.2 million in Q3 2025 and a low of $382.0 million during Q2 2023.
  • In the last 3 years, Castle Biosciences' Equity Average had a median value of $413.2 million in 2024 and averaged $417.5 million.
  • As far as peak fluctuations go, Castle Biosciences' Equity Average spiked by 382.11% in 2021, and later fell by 8.23% in 2023.
  • Castle Biosciences' Equity Average (Quarterly) stood at $411.7 million in 2021, then dropped by 1.56% to $405.3 million in 2022, then declined by 4.14% to $388.5 million in 2023, then climbed by 15.42% to $448.4 million in 2024, then climbed by 6.64% to $461.2 million in 2025.
  • Its Equity Average was $461.2 million in Q3 2025, compared to $447.8 million in Q2 2025 and $448.1 million in Q1 2025.